Business context and reporting period
Issuer identification: The filing is for Pieris Pharmaceuticals, Inc., not Pavella Therapeutics, Inc. It is the company’s Form 10-K for the fiscal year ended December 31, 2015, filed March 23, 2016; it reports annual results, not Q4-only results. Pieris is a clinical-stage biotechnology company developing Anticalin-based therapeutics. It has no approved products and no product-sales revenue.
Lead programs were PRS-080 for CKD-related functional iron deficiency anemia, PRS-060 for asthma, and the 300-Series immuno-oncology programs, including PRS-343. PRS-080 completed a Phase Ia healthy-volunteer study in 2015; its Phase Ib study in hemodialysis patients began in Q1 2016. PRS-060 and PRS-343 remained preclinical.
Financial and operating performance
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | $2.93 million | $5.37 million |
| Research and development expense | $8.24 million | $5.60 million |
| General and administrative expense | $8.37 million | $6.96 million |
| Loss from operations | $13.68 million | $7.20 million |
| Net loss | $14.06 million | $9.85 million |
| Net loss per share, basic and diluted | $0.41 | $0.71 |
| Net cash used in operating activities | $12.71 million | $5.07 million |
| Cash and cash equivalents at year-end | $29.35 million | $18.47 million |
Revenue came from collaboration milestones, research services, grants and other items—not product sales. Milestone revenue was $2.54 million in 2015 versus $3.18 million in 2014; grant and other revenue was $0.39 million versus $0.83 million. There was no upfront-payment revenue recognized in 2015. Operating expenses rose about 32%, while revenue fell about 45%; consequently, operating loss widened. The lower 2015 loss per share despite a larger net loss reflects a substantially higher weighted-average share count following equity issuances.
At December 31, 2015, total current assets were $31.66 million and current liabilities were $2.80 million; total liabilities were $2.82 million. The balance sheet showed no bank loan or other debt outstanding at year-end. Cash flow from financing was $24.62 million, primarily reflecting the July 2015 public offering, which generated approximately $25.8 million net proceeds. The company reported no off-balance-sheet arrangements. No meaningful product gross margin is reported because there were no product sales.
Material changes, outlook and key risks
- Spending and losses: R&D increased $2.64 million, principally from 300-Series program costs; G&A rose $1.41 million, including public-company costs. Operating cash use more than doubled year over year.
- Financing and dilution: The July 2015 offering raised $28.3 million gross and $25.8 million net. Shares outstanding increased to 39.83 million from 29.28 million at year-end 2014. The company stated that year-end cash was expected to fund operations and capital expenditures for at least the next 12 months, while also warning that additional capital would be needed and might not be available on acceptable terms.
- Management outlook: Pieris expected R&D expenses to increase significantly in 2016. It planned to complete the PRS-080 Phase Ib study during 2016 and intended to begin a Phase I trial of PRS-060 in 2017, subject to preclinical results. These are plans, not assurances.
- Partnership: A December 2015 Roche collaboration covered an undisclosed cancer immunotherapy target. Roche’s $6.5 million upfront payment was received in January 2016, with research funding and potential milestones and royalties; potential total payments could exceed $415 million, excluding royalties, if milestones and other conditions are met.
- Unusual legal item: TUM arbitration resulted in a €0.9 million (reported as approximately $0.9 million) award, plus $0.2 million interest expense; the tribunal awarded Pieris €0.1 million for legal fees. The company accepted and paid the award. The filing records $0.6 million of 2015 R&D expense related to the settlement, in addition to a previously recorded $0.3 million liability.
- Principal risks: The company has a limited clinical-stage operating history, ongoing losses and financing needs; candidates may fail in development or face regulatory delays, competition, or reimbursement barriers. It depends on third-party CROs and a single CMO for clinical supplies, has foreign-currency exposure, and relies on intellectual-property rights that include licensed TUM technology. It also disclosed potential dilution and possible resale pressure from a registration statement covering substantial existing shares.
- Controls and audit: Management said internal control over financial reporting was effective at year-end 2015 and that a prior material weakness had been remediated. The auditor gave an unqualified opinion on the financial statements but did not express an opinion on internal-control effectiveness.
Most important facts to verify
- Confirm the issuer: this filing identifies Pieris Pharmaceuticals, Inc.; it does not identify Pavella Therapeutics, Inc.
- Review the audited statements and cash-flow details, including the $12.71 million operating cash burn, year-end cash, and the company’s stated minimum 12-month funding runway.
- Check subsequent clinical progress and actual timing/results for PRS-080, PRS-060 and PRS-343 against the filing’s plans.
- Verify the Roche upfront payment, research funding and contractual conditions underlying contingent milestone and royalty potential; do not treat the stated maximum as committed revenue.
- Review equity dilution, outstanding options and warrants, and the resale registration statement covering approximately 27.3 million shares.
- Note a narrative inconsistency: one MD&A passage describes 2014 net income of $9.8 million, but the audited statements report a 2014 net loss of $9.85 million; the audited figures are used above.